Mark Barrett, formerly global head of strategy and business development at pharmaceutical firm Sanofi Genzyme, has joined the life sciences team of investment firm Frazier Healthcare Partners as entrepreneur-in-residence.
Barrett was responsible for Sanofi’s global rare diseases, immunology, multiple sclerosis and oncology businesses. He led the transaction team on Sanofi Genzyme’s $700m acquisition of a 12% stake in biopharmaceutical company Alnylam Pharmaceuticals in 2014.
Barrett also played a key role in Sanofi Genzyme’s $65m investment in gene therapy developer Voyager Therapeutics in February 2015.
Before joining the company in 2013, Barrett was director of business development for pharmaceutical group Johnson & Johnson between 2002 and 2009, before being promoted to senior director of business development and new ventures, a position he held until 2012.
Barrett will perform his new role while continuing to serve as CEO of Yosemite Therapeutics, a company co-founded with Frazier that is focusing on developing treatments to address unmet medical needs in serious illnesses.
– Photo of Mark Barrett courtesy of LinkedIn